Discovery of novel hydroxime-based NLRP3 inflammasome inhibitors with reduced hepatotoxicity
Bioorganic & Medicinal Chemistry Letters · 2026-08 · 137 · 130666
DOI: 10.1016/j.bmcl.2026.130666 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-08. Verfasst von Wei Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, The Second Military Medical University, 325 Guohe Road, Shanghai 200433, the People's Republic of China; Shanghai Frontiers Scien…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Drug Discovery, Oximes. Die Arbeit nennt 26 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome plays a critical role in mediating intracellular caspase-1 activation, IL-1β release, and pyroptosis with its excessive activation being closely associated with the pathogenesis of various inflammatory diseases. In this study, a series of novel hydroxime-based NLRP3 inflammasome inhibitors were designed and synthesized. Among them, compound ZM734 exhibited potent inhibitory activity against IL-1β secretion in mouse bone marrow-derived macrophages (BMDMs). In addition, compound ZM734 effectively inhibited NLRP3 inflammasome activation induced by diverse stimuli. Compound ZM734 demonstrated a definite protective effect and was capable of alleviating pulmonary inflammation in a C57BL/6 mouse model of acute lung injury. Notably, the cytotoxicity of compound ZM734 toward human hepatic stellate LX-2 cells was significantly reduced. Furthermore, the increases in serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mice treated with compound ZM734 at the same dose were significantly lower than that of MCC950. These findings thereby provide a new direction to the further structural optimization for the discovery of low toxicity NLRP3 inflammasome inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, The Second Military Medical University, 325 Guohe Road, Shanghai 200433, the People's Republic of China; Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key…
- School of Pharmacy, The Second Military Medical University, 325 Guohe Road, Shanghai 200433, the People's Republic of China; Faculty of Chemical Engineering and Energy Technology, Shanghai Institute of Technology, 100 H…
- School of Pharmacy, The Second Military Medical University, 325 Guohe Road, Shanghai 200433, the People's Republic of China.
- Faculty of Chemical Engineering and Energy Technology, Shanghai Institute of Technology, 100 Haiquan Road, Shanghai 201418, the People's Republic of China.
- Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, 130 Meilong Road, Shangha…
- Department of Radiation Oncology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, the People's Republic of China. Electronic address: chyyzhj@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, W., Gao, Y., Huang, A., Li, M., Ye, S., Wu, Y., Zhang, Y., Zhang, H., & Miao, Z. (2026). Discovery of novel hydroxime-based NLRP3 inflammasome inhibitors with reduced hepatotoxicity. Bioorganic & Medicinal Chemistry Letters, 137, 130666. https://doi.org/10.1016/j.bmcl.2026.130666
Vancouver
Li W, Gao Y, Huang A, Li M, Ye S, Wu Y, et al. Discovery of novel hydroxime-based NLRP3 inflammasome inhibitors with reduced hepatotoxicity. Bioorganic & Medicinal Chemistry Letters. 2026;137:130666. doi:10.1016/j.bmcl.2026.130666
BibTeX
@article{Li2026,
author = {Li, Wei and Gao, Yaxuan and Huang, Anhua and Li, Mochenxuan and Ye, Shuang and Wu, Yuelin and Zhang, Yongqiang and Zhang, Huojun and Miao, Zhenyuan},
title = {Discovery of novel hydroxime-based NLRP3 inflammasome inhibitors with reduced hepatotoxicity},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2026},
volume = {137},
pages = {130666},
doi = {10.1016/j.bmcl.2026.130666}
}
EUVIMED